

7 July 2015 EMA/HMPC/46758/2015 Committee on Herbal Medicinal Products (HMPC)

European Union herbal monograph on *Pistacia lentiscus* L., resin (mastix)

Draft

| Discussion in Working Party on European Union monographs and list | November 2014 | |
|---|-----------------|--|
| (MLWP) | January 2015 | |
| | March 2105 | |
| | May 2015 | |
| Adoption by Committee on Herbal Medicinal Products (HMPC) for release | 07 July 2015 | |
| for consultation | 07 Suly 2013 | |
| Start of public consultation | 22 July 2015 | |
| End of consultation (deadline for comments). Comments should be | 31 October 2015 | |
| provided using this template to hmpc.secretariat@ema.europa.eu | 31 October 2015 | |
| Re-discussion in MLWP | | |
| Adoption by HMPC | | |

| Keywords | Herbal medicinal products; HMPC; European Union herbal monographs; |
|----------|--|
| | traditional use; Pistacia lentiscus L., resin, Mastix, Mastic tree resin |

| BG (bulgarski): Мастикс | LT (lietuvių kalba): mastikà |
|---|---|
| CS (čeština): list/pryskyřice pistácie lentišku | LV (latviešu valoda): Mastikas pistācijas sveķi |
| DA (dansk): Mastiks | MT (Malti): reżina tad-Deru |
| DE (Deutsch): Mastix | NL (Nederlands): Mastiekboom, hars (mastiek) |
| EL (elliniká): Ρητίνη Μαστίχης Χίου | PL (polski): Mastyks |
| EN (English): Mastic tree resin | PT (português): Mastique |
| ES (español): Lentisco, resina de | RO (română): |
| ET (eesti keel): mastiks | SK (slovenčina): Mastix |
| FI (suomi): mastiksipistaasi, hartsi | SL (slovenščina): mastiks |
| FR (français): Mastic | SV (svenska): Mastix |
| HR (hrvatski): Mastiks | IS (íslenska): |
| HU (magyar): pisztáciagyanta | NO (norsk): Mastiks |
| IT (italiano): lentisco resina | |
| | |

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact



An agency of the European Union

 \odot European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged.

European Union herbal monograph on *Pistacia lentiscus* L., resin (mastix)

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1, 2}

| Well-established use | Traditional use |
|----------------------|--|
| | With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended |
| | Pistacia lentiscus L., resin (mastix) |
| | i) Herbal substance |
| | Not applicable |
| | ii) Herbal preparations |
| | Powdered herbal substance |

3. Pharmaceutical form

| Well-established use | Traditional use |
|----------------------|--|
| | Powdered herbal substance in solid dosage form for oral use. |
| | Powdered herbal substance in semi-solid dosage form for cutaneous use. |

4. Clinical particulars

4.1. Therapeutic indications

| Well-established use | Traditional use |
|----------------------|--|
| | Indication 1) |
| | Traditional herbal medicinal product used in mild dyspeptic disorders. |

¹ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

² The material complies with the Ph. Eur. monograph (ref.: 1876)

| Well-established use | Traditional use |
|----------------------|--|
| | Indication 2) |
| | Traditional herbal medicinal product used for the symptomatic treatment of minor inflammations of the skin and as an aid in healing of minor wounds. |
| | The product is a traditional herbal medicinal product for use in the specified indications exclusively based upon long-standing use. |

4.2. Posology and method of administration

| Well-established use | Traditional use |
|----------------------|---|
| | Posology |
| | Indication 1) |
| | Adults and elderly |
| | Single dose: 0.35-0.5 g Daily dose: 3-4 times daily |
| | The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). Indication 2) |
| | Adolescents, adults and elderly |
| | Semi-solid preparations containing 9-11% of the powdered herbal substance to be applied as a thin layer on the affected area up to 3 times daily. |
| | The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). |
| | Duration of use |
| | Indication 1) |
| | If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. |
| | Indication 2) |
| | If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. |

| Well-established use | Traditional use |
|----------------------|--------------------------|
| | Method of administration |
| | Indication 1) |
| | Oral use |
| | Indication 2) |
| | Cutaneous use |

4.3. Contraindications

| Well-established use | Traditional use |
|----------------------|---|
| | Hypersensitivity to the active substance. |

4.4. Special warnings and precautions for use

| Well-established use | Traditional use |
|----------------------|---|
| | Indication 1) |
| | The use in children and adolescents under 18 years of age has not been established due to lack of adequate data. |
| | Indication 2) |
| | The use in children under 12 years of age has not been established due to lack of adequate data. |
| | If signs of skin infection are observed, a doctor or a qualified health care practitioner should be consulted. |
| | If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. |

4.5. Interactions with other medicinal products and other forms of interaction

| Well-established use | Traditional use |
|----------------------|-----------------|
| | None reported. |

4.6. Fertility, pregnancy and lactation

| Well-established use | Traditional use |
|----------------------|------------------------------|
| | No fertility data available. |

| Well-established use | Traditional use |
|----------------------|--|
| | Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. |

4.7. Effects on ability to drive and use machines

| Well-established use | Traditional use |
|----------------------|--|
| | No studies on the effect on the ability to drive and use machines have been performed. |

4.8. Undesirable effects

| Well-established use | Traditional use |
|----------------------|---|
| | None known. |
| | If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted. |

4.9. Overdose

| Well-established use | Traditional use |
|----------------------|--|
| | No case of overdose has been reported. |

5. Pharmacological properties

5.1. Pharmacodynamic properties

| Well-established use | Traditional use |
|----------------------|--|
| | Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended. |

5.2. Pharmacokinetic properties

| Well-established use | Traditional use |
|----------------------|--|
| | Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended. |

5.3. Preclinical safety data

| Well-established use | Traditional use |
|----------------------|--|
| | Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. |
| | Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed. |

6. Pharmaceutical particulars

| Well-established use | Traditional use |
|----------------------|-----------------|
| | Not applicable. |

7. Date of compilation/last revision

7 July 2015